Royalty Pharma plc (RPRX): Shareholders' Equity
$9.71B
As of 2025-12-31
$9.79B
As of 2026-06-30
+0.7%
3-year compound annual growth
-0.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.71B | -6.1% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $10.34B | +2.6% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $10.08B | +5.9% | 2026-02-11, Balance as of period end |
| 2022-12-31 | $9.53B | -7.1% | 2025-02-12, Balance as of period end |
| 2021-12-31 | $10.25B | +3.6% | 2024-02-15, Balance as of period end |
| 2020-12-31 | $9.90B | +61.1% | 2023-02-15, Balance as of period end |
| 2019-12-31 | $6.14B | +34.9% | 2022-02-15, Balance as of period end |
| 2018-12-31 | $4.55B | n/a | 2021-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $9.71B | -6.1% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $1.14B | -25.3% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | -$70.79M | n/m |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $7.10B | +10.1% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $6.09B | +7.6% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | -$205.31M | n/m |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $789.18M | n/m |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $385.48M | +34.9% |
| Alkermes plc. (ALKS) | 2025-12-31 | $1.82B | +24.2% |
Compare RPRX, SRPT, AMRX, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗